PMID- 24622501
OWN - NLM
STAT- MEDLINE
DCOM- 20150529
LR  - 20211203
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 3
DP  - 2014
TI  - YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor 
      prognosis for ovarian cancer patients.
PG  - e91770
LID - 10.1371/journal.pone.0091770 [doi]
LID - e91770
AB  - YAP is a key component of the Hippo signaling pathway and plays a critical role 
      in the development and progression of multiple cancer types, including ovarian 
      cancer. However, the effects of YAP on ovarian cancer development in vivo and its 
      downstream effectors remain uncertain. In this study we found that strong YAP 
      expression was associated with poor ovarian cancer patient survival. 
      Specifically, we showed for the first time that high YAP expression levels were 
      positively correlated with TEAD4 gene expression, and their co-expression was a 
      prognostic marker for poor ovarian cancer survival. Hyperactivation of YAP by 
      mutating its five inhibitory phosphorylation sites (YAP-5SA) increased ovarian 
      cancer cell proliferation, resistance to chemotherapeutic drugs, cell migration, 
      and anchorage-independent growth. In contrast, expression of a dominant negative 
      YAP mutant reversed these phenotypes in ovarian cancer cells both in vitro and in 
      vivo. Our results suggested that YAP caused these effects by promoting an 
      epithelial-to-mesenchymal transition. Thus, YAP promotes ovarian cancer cell 
      growth and tumorigenesis both in vitro and in vivo. Further, high YAP and TEAD4 
      expression is a prognostic marker for ovarian cancer progression and a potential 
      target for ovarian cancer treatment.
FAU - Xia, Yan
AU  - Xia Y
AD  - Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang 
      University, Hangzhou, China.
FAU - Chang, Ting
AU  - Chang T
AD  - Department of Neurology, Tangdu Hospital, the Fourth Military Medical University, 
      Xi'an, China.
FAU - Wang, Yingmei
AU  - Wang Y
AD  - Department of Pathology, Xijing Hospital, the Fourth Military Medical University, 
      Xi'an, China.
FAU - Liu, Yixiong
AU  - Liu Y
AD  - Department of Pathology, Xijing Hospital, the Fourth Military Medical University, 
      Xi'an, China.
FAU - Li, Wenhui
AU  - Li W
AD  - Department of Obstetrics and Gynecology, Xijing Hospital, the Fourth Military 
      Medical University, Xi'an, China.
FAU - Li, Ming
AU  - Li M
AD  - The Affiliated Guangren Hospital, Xi'an Jiaotong University, Xi'an, China.
FAU - Fan, Heng-Yu
AU  - Fan HY
AD  - Life Sciences Institute and Innovation Center for Cell Biology, Zhejiang 
      University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140312
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Muscle Proteins)
RN  - 0 (Phosphoproteins)
RN  - 0 (TEA Domain Transcription Factors)
RN  - 0 (TEAD4 protein, human)
RN  - 0 (Transcription Factors)
RN  - 0 (YAP-Signaling Proteins)
RN  - 0 (YAP1 protein, human)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
EIN - PLoS One. 2016;11(3):e0152712. PMID: 27015277
MH  - Active Transport, Cell Nucleus/drug effects
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - *Carcinogenesis/drug effects
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Nucleus/drug effects/metabolism
MH  - Cell Proliferation/drug effects
MH  - Cell Transformation, Neoplastic
MH  - Cisplatin/pharmacology
MH  - DNA-Binding Proteins/metabolism
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Mice
MH  - Muscle Proteins/metabolism
MH  - Ovarian Neoplasms/*diagnosis/metabolism/*pathology
MH  - Paclitaxel/pharmacology
MH  - Phosphoproteins/*metabolism
MH  - Prognosis
MH  - TEA Domain Transcription Factors
MH  - Transcription Factors/metabolism
MH  - YAP-Signaling Proteins
PMC - PMC3951505
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/03/14 06:00
MHDA- 2015/05/30 06:00
PMCR- 2014/03/12
CRDT- 2014/03/14 06:00
PHST- 2014/01/10 00:00 [received]
PHST- 2014/02/14 00:00 [accepted]
PHST- 2014/03/14 06:00 [entrez]
PHST- 2014/03/14 06:00 [pubmed]
PHST- 2015/05/30 06:00 [medline]
PHST- 2014/03/12 00:00 [pmc-release]
AID - PONE-D-14-00424 [pii]
AID - 10.1371/journal.pone.0091770 [doi]
PST - epublish
SO  - PLoS One. 2014 Mar 12;9(3):e91770. doi: 10.1371/journal.pone.0091770. eCollection 
      2014.